Crewe Advisors LLC Acquires Shares of 29 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 29 shares of the biopharmaceutical company’s stock, valued at approximately $28,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. West Paces Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the period. MCF Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Criterion Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $37,000. BOK Financial Private Wealth Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $37,000. Finally, Partnership Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $55,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders sold 65,074 shares of company stock valued at $64,546,123 over the last three months. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.3 %

Shares of REGN stock traded up $3.33 on Thursday, hitting $1,064.19. 525,090 shares of the stock were exchanged, compared to its average volume of 468,509. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $117.26 billion, a P/E ratio of 31.44, a price-to-earnings-growth ratio of 2.19 and a beta of 0.13. The business has a 50-day moving average of $1,031.92 and a 200 day moving average of $975.57. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $723.56 and a fifty-two week high of $1,106.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.02 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. TD Cowen lifted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, June 24th. JPMorgan Chase & Co. upped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Monday, June 17th. Finally, Barclays upped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,074.95.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.